[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fFAqsVtG5IchVqCyQV5XZ6v_nk2O6yJJWpf0R78XyVYc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"Uppsala University",[6,4],"Uppsala University Hospital",452,false,99,6,3475131,22,373,[15,18,21,24,26,29,31,34],{"name":16,"count":17},"Obesity",11,{"name":19,"count":20},"Chronic Pain",10,{"name":22,"count":23},"Sepsis",9,{"name":25,"count":23},"Depression",{"name":27,"count":28},"Breast Cancer",8,{"name":30,"count":28},"Acute Kidney Injury",{"name":32,"count":33},"Quality of Life",7,{"name":35,"count":33},"Pain",[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04185831","A MolEcularly Guided Anti-Cancer Drug Off-Label Trial","2024-01-31","Atezolizumab",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06245629","Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma","2025-03-31","Bortezomib-bendamustine-melphalan",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT02749331","Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy","2025-08","AdVince",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT04861558","Efficacy of Hyperthermic Intraperitoneal Chemotherapy","2025-12","5Fluorouracil",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT02901184","Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction","2026-12","Spironolactone",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT06876870","MR-Evaluation of Renal Function in Anesthetized Pediatric Patients","2026-12-10","Anesthesia Maintenance Agent",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06446401","The Case of \"Triple\" Versus \"Double\" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer","2026-12-31","ADT + NHT + Docetaxel",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT06002659","CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)","2027-12-30","CAR20(NAP)-T",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT04323566","Rituximab Treatment for Psychosis And\u002For Obsessive Compulsive Disorder with Probable Immune System Involvement","2028-04-01","Rituximab",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT05061030","Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents","2028-09","the ATMP Protrans",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,123,149,167,193,218,236,254,275,297,320,338,356,378,408,433,458,476,494,512,535,553,575,626,652,687,721,758,794,812,830,860,878,896,914,932,950,976,994,1023,1041,1059,1077,1095,1122,1140,1167,1185,1203,1230,1248,1275,1293,1311,1337,1364,1398,1422,1455,1473,1498,1523,1548,1574,1598,1624,1649,1673,1697,1723,1748,1773,1791,1815,1838,1861,1890,1915,1933,1960,1978,2003,2033,2070,2105,2133,2151,2169,2187,2205,2223,2247,2277,2301,2326,2350,2376,2394,2420,2438,2464,2489,2513,2537,2561,2588,2614,2639,2668,2686,2704,2722,2740],{"intervention":66,"totalTrials":96,"cells":97},1,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":121},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":96,"soonestReadout":65},[109],{"nctId":63,"briefTitle":64,"status":110,"phases":111,"primaryCompletion":65,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":120},"NOT_YET_RECRUITING",[92],"2027-06-20","2025-10-01",50,[116,117,118,119],"Renal Blood Flow","Anesthesia","MRI","Renal Oxygenation",[66],{"trials":122,"activeCount":100},[],{"intervention":124,"totalTrials":96,"cells":125},"Pivmecillinam",{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":134,"NA":147},{"trials":127,"activeCount":100},[],{"trials":129,"activeCount":100},[],{"trials":131,"activeCount":100},[],{"trials":133,"activeCount":100},[],{"trials":135,"activeCount":96,"soonestReadout":141},[136],{"nctId":137,"briefTitle":138,"status":139,"phases":140,"primaryCompletion":141,"completion":141,"start":55,"enrollment":142,"conditions":143,"interventions":145},"NCT07236944","Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","RECRUITING",[92],"2029-03",560,[144],"Febrile Urinary Tract Infection",[124,146],"Standard of Care",{"trials":148,"activeCount":100},[],{"intervention":146,"totalTrials":96,"cells":150},{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":157,"PHASE4":159,"NA":165},{"trials":152,"activeCount":100},[],{"trials":154,"activeCount":100},[],{"trials":156,"activeCount":100},[],{"trials":158,"activeCount":100},[],{"trials":160,"activeCount":96,"soonestReadout":141},[161],{"nctId":137,"briefTitle":138,"status":139,"phases":162,"primaryCompletion":141,"completion":141,"start":55,"enrollment":142,"conditions":163,"interventions":164},[92],[144],[124,146],{"trials":166,"activeCount":100},[],{"intervention":168,"totalTrials":96,"cells":169},"nivolumab or pembrolizumab",{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":189,"NA":191},{"trials":171,"activeCount":100},[],{"trials":173,"activeCount":100},[],{"trials":175,"activeCount":100},[],{"trials":177,"activeCount":96,"soonestReadout":182},[178],{"nctId":179,"briefTitle":180,"status":139,"phases":181,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":188},"NCT06488482","Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma",[91],"2030-09","2033-09","2024-12-19",1792,[187],"High-risk Melanoma",[168],{"trials":190,"activeCount":100},[],{"trials":192,"activeCount":100},[],{"intervention":56,"totalTrials":96,"cells":194},{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":199,"PHASE3":201,"PHASE4":214,"NA":216},{"trials":196,"activeCount":100},[],{"trials":198,"activeCount":100},[],{"trials":200,"activeCount":100},[],{"trials":202,"activeCount":96,"soonestReadout":55},[203],{"nctId":53,"briefTitle":54,"status":139,"phases":204,"primaryCompletion":55,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":211},[91],"2029-12","2021-05-01",213,[209,210],"Colorectal Cancer","Peritoneal Metastases",[56,212,213],"Irinotecan","Oxaliplatin",{"trials":215,"activeCount":100},[],{"trials":217,"activeCount":100},[],{"intervention":212,"totalTrials":96,"cells":219},{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":226,"PHASE4":232,"NA":234},{"trials":221,"activeCount":100},[],{"trials":223,"activeCount":100},[],{"trials":225,"activeCount":100},[],{"trials":227,"activeCount":96,"soonestReadout":55},[228],{"nctId":53,"briefTitle":54,"status":139,"phases":229,"primaryCompletion":55,"completion":205,"start":206,"enrollment":207,"conditions":230,"interventions":231},[91],[209,210],[56,212,213],{"trials":233,"activeCount":100},[],{"trials":235,"activeCount":100},[],{"intervention":213,"totalTrials":96,"cells":237},{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":250,"NA":252},{"trials":239,"activeCount":100},[],{"trials":241,"activeCount":100},[],{"trials":243,"activeCount":100},[],{"trials":245,"activeCount":96,"soonestReadout":55},[246],{"nctId":53,"briefTitle":54,"status":139,"phases":247,"primaryCompletion":55,"completion":205,"start":206,"enrollment":207,"conditions":248,"interventions":249},[91],[209,210],[56,212,213],{"trials":251,"activeCount":100},[],{"trials":253,"activeCount":100},[],{"intervention":61,"totalTrials":96,"cells":255},{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":271,"NA":273},{"trials":257,"activeCount":100},[],{"trials":259,"activeCount":100},[],{"trials":261,"activeCount":100},[],{"trials":263,"activeCount":96,"soonestReadout":60},[264],{"nctId":58,"briefTitle":59,"status":139,"phases":265,"primaryCompletion":60,"completion":60,"start":266,"enrollment":267,"conditions":268,"interventions":270},[91],"2017-11-23",2000,[269],"Heart Failure With Preserved Ejection Fraction",[61],{"trials":272,"activeCount":100},[],{"trials":274,"activeCount":100},[],{"intervention":51,"totalTrials":96,"cells":276},{"EARLY_PHASE1":277,"PHASE1":279,"PHASE2":281,"PHASE3":291,"PHASE4":293,"NA":295},{"trials":278,"activeCount":100},[],{"trials":280,"activeCount":100},[],{"trials":282,"activeCount":96,"soonestReadout":50},[283],{"nctId":48,"briefTitle":49,"status":284,"phases":285,"primaryCompletion":50,"completion":55,"start":286,"enrollment":287,"conditions":288,"interventions":290},"ACTIVE_NOT_RECRUITING",[89,90],"2016-03",35,[289],"Neuroendocrine Tumors",[51],{"trials":292,"activeCount":100},[],{"trials":294,"activeCount":100},[],{"trials":296,"activeCount":100},[],{"intervention":76,"totalTrials":96,"cells":298},{"EARLY_PHASE1":299,"PHASE1":301,"PHASE2":303,"PHASE3":314,"PHASE4":316,"NA":318},{"trials":300,"activeCount":100},[],{"trials":302,"activeCount":100},[],{"trials":304,"activeCount":96,"soonestReadout":75},[305],{"nctId":73,"briefTitle":74,"status":139,"phases":306,"primaryCompletion":75,"completion":75,"start":307,"enrollment":308,"conditions":309,"interventions":311},[89,90],"2024-05-01",18,[310],"B-cell Lymphoma",[76,312,313],"Cyclophosphamide","Fludarabine",{"trials":315,"activeCount":100},[],{"trials":317,"activeCount":100},[],{"trials":319,"activeCount":100},[],{"intervention":312,"totalTrials":96,"cells":321},{"EARLY_PHASE1":322,"PHASE1":324,"PHASE2":326,"PHASE3":332,"PHASE4":334,"NA":336},{"trials":323,"activeCount":100},[],{"trials":325,"activeCount":100},[],{"trials":327,"activeCount":96,"soonestReadout":75},[328],{"nctId":73,"briefTitle":74,"status":139,"phases":329,"primaryCompletion":75,"completion":75,"start":307,"enrollment":308,"conditions":330,"interventions":331},[89,90],[310],[76,312,313],{"trials":333,"activeCount":100},[],{"trials":335,"activeCount":100},[],{"trials":337,"activeCount":100},[],{"intervention":313,"totalTrials":96,"cells":339},{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":350,"PHASE4":352,"NA":354},{"trials":341,"activeCount":100},[],{"trials":343,"activeCount":100},[],{"trials":345,"activeCount":96,"soonestReadout":75},[346],{"nctId":73,"briefTitle":74,"status":139,"phases":347,"primaryCompletion":75,"completion":75,"start":307,"enrollment":308,"conditions":348,"interventions":349},[89,90],[310],[76,312,313],{"trials":351,"activeCount":100},[],{"trials":353,"activeCount":100},[],{"trials":355,"activeCount":100},[],{"intervention":86,"totalTrials":96,"cells":357},{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":372,"PHASE4":374,"NA":376},{"trials":359,"activeCount":100},[],{"trials":361,"activeCount":100},[],{"trials":363,"activeCount":96,"soonestReadout":85},[364],{"nctId":83,"briefTitle":84,"status":284,"phases":365,"primaryCompletion":85,"completion":366,"start":367,"enrollment":368,"conditions":369,"interventions":371},[89,90],"2028-12","2022-01-14",66,[370],"Type1diabetes",[86],{"trials":373,"activeCount":100},[],{"trials":375,"activeCount":100},[],{"trials":377,"activeCount":100},[],{"intervention":81,"totalTrials":96,"cells":379},{"EARLY_PHASE1":380,"PHASE1":382,"PHASE2":384,"PHASE3":402,"PHASE4":404,"NA":406},{"trials":381,"activeCount":100},[],{"trials":383,"activeCount":100},[],{"trials":385,"activeCount":96,"soonestReadout":80},[386],{"nctId":78,"briefTitle":79,"status":387,"phases":388,"primaryCompletion":80,"completion":389,"start":390,"enrollment":391,"conditions":392,"interventions":401},"ENROLLING_BY_INVITATION",[90],"2028-12-01","2022-05-01",40,[393,394,395,396,397,398,399,400],"Obsessive-Compulsive Disorder","Obsessive-Compulsive Behavior","Schizophrenia","Delusional Disorder","Brief Psychotic Disorder","Schizo Affective Disorder","Other Psychoses","Unspecified Psychosis",[81],{"trials":403,"activeCount":100},[],{"trials":405,"activeCount":100},[],{"trials":407,"activeCount":100},[],{"intervention":409,"totalTrials":96,"cells":410},"Sequential treatment with rituximab and cladribine",{"EARLY_PHASE1":411,"PHASE1":413,"PHASE2":415,"PHASE3":427,"PHASE4":429,"NA":431},{"trials":412,"activeCount":100},[],{"trials":414,"activeCount":100},[],{"trials":416,"activeCount":96,"soonestReadout":421},[417],{"nctId":418,"briefTitle":419,"status":110,"phases":420,"primaryCompletion":421,"completion":421,"start":422,"enrollment":423,"conditions":424,"interventions":426},"NCT07517185","The HIt HArd and hiT Early in Multiple Sclerosis Trial",[90],"2030-12-31","2026-04-15",60,[425],"Relapsing-remitting Multiple Sclerosis",[409],{"trials":428,"activeCount":100},[],{"trials":430,"activeCount":100},[],{"trials":432,"activeCount":100},[],{"intervention":41,"totalTrials":96,"cells":434},{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":452,"PHASE4":454,"NA":456},{"trials":436,"activeCount":100},[],{"trials":438,"activeCount":100},[],{"trials":440,"activeCount":96,"soonestReadout":40},[441],{"nctId":38,"briefTitle":39,"status":284,"phases":442,"primaryCompletion":40,"completion":443,"start":444,"enrollment":445,"conditions":446,"interventions":448},[90],"2024-10","2020-10-20",167,[447],"Solid Tumor",[41,449,450,451],"Everolimus","Cobimetinib","Niraparib",{"trials":453,"activeCount":100},[],{"trials":455,"activeCount":100},[],{"trials":457,"activeCount":100},[],{"intervention":449,"totalTrials":96,"cells":459},{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":470,"PHASE4":472,"NA":474},{"trials":461,"activeCount":100},[],{"trials":463,"activeCount":100},[],{"trials":465,"activeCount":96,"soonestReadout":40},[466],{"nctId":38,"briefTitle":39,"status":284,"phases":467,"primaryCompletion":40,"completion":443,"start":444,"enrollment":445,"conditions":468,"interventions":469},[90],[447],[41,449,450,451],{"trials":471,"activeCount":100},[],{"trials":473,"activeCount":100},[],{"trials":475,"activeCount":100},[],{"intervention":450,"totalTrials":96,"cells":477},{"EARLY_PHASE1":478,"PHASE1":480,"PHASE2":482,"PHASE3":488,"PHASE4":490,"NA":492},{"trials":479,"activeCount":100},[],{"trials":481,"activeCount":100},[],{"trials":483,"activeCount":96,"soonestReadout":40},[484],{"nctId":38,"briefTitle":39,"status":284,"phases":485,"primaryCompletion":40,"completion":443,"start":444,"enrollment":445,"conditions":486,"interventions":487},[90],[447],[41,449,450,451],{"trials":489,"activeCount":100},[],{"trials":491,"activeCount":100},[],{"trials":493,"activeCount":100},[],{"intervention":451,"totalTrials":96,"cells":495},{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":506,"PHASE4":508,"NA":510},{"trials":497,"activeCount":100},[],{"trials":499,"activeCount":100},[],{"trials":501,"activeCount":96,"soonestReadout":40},[502],{"nctId":38,"briefTitle":39,"status":284,"phases":503,"primaryCompletion":40,"completion":443,"start":444,"enrollment":445,"conditions":504,"interventions":505},[90],[447],[41,449,450,451],{"trials":507,"activeCount":100},[],{"trials":509,"activeCount":100},[],{"trials":511,"activeCount":100},[],{"intervention":71,"totalTrials":96,"cells":513},{"EARLY_PHASE1":514,"PHASE1":516,"PHASE2":518,"PHASE3":520,"PHASE4":522,"NA":524},{"trials":515,"activeCount":100},[],{"trials":517,"activeCount":100},[],{"trials":519,"activeCount":100},[],{"trials":521,"activeCount":100},[],{"trials":523,"activeCount":100},[],{"trials":525,"activeCount":96,"soonestReadout":70},[526],{"nctId":68,"briefTitle":69,"status":139,"phases":527,"primaryCompletion":70,"completion":528,"start":529,"enrollment":530,"conditions":531,"interventions":533},[],"2031-12-31","2024-10-20",1400,[532],"Prostate Cancer",[71,534],"ADT + NHT",{"intervention":534,"totalTrials":96,"cells":536},{"EARLY_PHASE1":537,"PHASE1":539,"PHASE2":541,"PHASE3":543,"PHASE4":545,"NA":547},{"trials":538,"activeCount":100},[],{"trials":540,"activeCount":100},[],{"trials":542,"activeCount":100},[],{"trials":544,"activeCount":100},[],{"trials":546,"activeCount":100},[],{"trials":548,"activeCount":96,"soonestReadout":70},[549],{"nctId":68,"briefTitle":69,"status":139,"phases":550,"primaryCompletion":70,"completion":528,"start":529,"enrollment":530,"conditions":551,"interventions":552},[],[532],[71,534],{"intervention":46,"totalTrials":96,"cells":554},{"EARLY_PHASE1":555,"PHASE1":557,"PHASE2":559,"PHASE3":561,"PHASE4":563,"NA":565},{"trials":556,"activeCount":100},[],{"trials":558,"activeCount":100},[],{"trials":560,"activeCount":100},[],{"trials":562,"activeCount":100},[],{"trials":564,"activeCount":100},[],{"trials":566,"activeCount":96,"soonestReadout":45},[567],{"nctId":43,"briefTitle":44,"status":139,"phases":568,"primaryCompletion":45,"completion":569,"start":570,"enrollment":571,"conditions":572,"interventions":574},[],"2025-11-30","2024-11-24",100,[573],"Myeloma Multiple",[46],{"intervention":576,"totalTrials":577,"cells":578},"Propofol",3,{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":597,"PHASE3":599,"PHASE4":601,"NA":624},{"trials":580,"activeCount":100},[],{"trials":582,"activeCount":100},[583],{"nctId":584,"briefTitle":585,"status":586,"phases":587,"primaryCompletion":588,"completion":589,"start":590,"enrollment":591,"conditions":592,"interventions":594},"NCT02571426","Renal Function During Pediatric Anesthesia","COMPLETED",[89],"2018-03","2019-04","2015-10",24,[593,117],"Renal Failure",[595,596],"Sevoflurane","propofol",{"trials":598,"activeCount":100},[],{"trials":600,"activeCount":100},[],{"trials":602,"activeCount":100},[603,615],{"nctId":604,"briefTitle":605,"status":586,"phases":606,"primaryCompletion":607,"completion":607,"start":608,"enrollment":609,"conditions":610,"interventions":614},"NCT01975064","Cancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane Anesthesia",[92],"2022-08-31","2013-11",5774,[611,612,613],"Breast Neoplasms","Colonic Neoplasms","Rectal Neoplasms",[576,595],{"nctId":616,"briefTitle":617,"status":586,"phases":618,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":622,"interventions":623},"NCT03336801","The Effect of Propofol or Sevoflurane on Renal Function",[92],"2020-01-10","2017-09-01",37,[30,117],[576,595],{"trials":625,"activeCount":100},[],{"intervention":595,"totalTrials":577,"cells":627},{"EARLY_PHASE1":628,"PHASE1":630,"PHASE2":636,"PHASE3":638,"PHASE4":640,"NA":650},{"trials":629,"activeCount":100},[],{"trials":631,"activeCount":100},[632],{"nctId":584,"briefTitle":585,"status":586,"phases":633,"primaryCompletion":588,"completion":589,"start":590,"enrollment":591,"conditions":634,"interventions":635},[89],[593,117],[595,596],{"trials":637,"activeCount":100},[],{"trials":639,"activeCount":100},[],{"trials":641,"activeCount":100},[642,646],{"nctId":604,"briefTitle":605,"status":586,"phases":643,"primaryCompletion":607,"completion":607,"start":608,"enrollment":609,"conditions":644,"interventions":645},[92],[611,612,613],[576,595],{"nctId":616,"briefTitle":617,"status":586,"phases":647,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":648,"interventions":649},[92],[30,117],[576,595],{"trials":651,"activeCount":100},[],{"intervention":653,"totalTrials":654,"cells":655},"Dapagliflozin",2,{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":670,"PHASE4":672,"NA":685},{"trials":657,"activeCount":100},[],{"trials":659,"activeCount":100},[],{"trials":661,"activeCount":100},[662],{"nctId":663,"briefTitle":664,"status":586,"phases":665,"primaryCompletion":286,"completion":286,"start":666,"enrollment":114,"conditions":667,"interventions":668},"NCT02313220","Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight",[90],"2014-12",[16],[653,669],"Exenatide",{"trials":671,"activeCount":100},[],{"trials":673,"activeCount":100},[674],{"nctId":675,"briefTitle":676,"status":586,"phases":677,"primaryCompletion":678,"completion":678,"start":286,"enrollment":679,"conditions":680,"interventions":682},"NCT02765204","A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes",[92],"2016-12",15,[681],"Diabetes Mellitus, Type 2",[653,683,684],"Saxagliptin","Glucose",{"trials":686,"activeCount":100},[],{"intervention":688,"totalTrials":654,"cells":689},"Dexmedetomidine",{"EARLY_PHASE1":690,"PHASE1":692,"PHASE2":694,"PHASE3":696,"PHASE4":698,"NA":719},{"trials":691,"activeCount":100},[],{"trials":693,"activeCount":100},[],{"trials":695,"activeCount":100},[],{"trials":697,"activeCount":100},[],{"trials":699,"activeCount":100},[700,709],{"nctId":701,"briefTitle":702,"status":586,"phases":703,"primaryCompletion":666,"completion":666,"start":704,"enrollment":114,"conditions":705,"interventions":708},"NCT02016391","Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours",[92],"2013-12",[706,707],"Cancer of Kidney and Renal Pelvis","Cancer of Liver",[688],{"nctId":710,"briefTitle":711,"status":586,"phases":712,"primaryCompletion":713,"completion":713,"start":714,"enrollment":715,"conditions":716,"interventions":718},"NCT02044224","Effects of Dexmedetomidine During IRE Procedures for Solid Tumours",[92],"2015-09","2014-01",30,[707,717],"Cancer of Pancreas",[688],{"trials":720,"activeCount":100},[],{"intervention":722,"totalTrials":654,"cells":723},"Metformin",{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":728,"PHASE3":741,"PHASE4":743,"NA":756},{"trials":725,"activeCount":100},[],{"trials":727,"activeCount":100},[],{"trials":729,"activeCount":100},[730],{"nctId":731,"briefTitle":732,"status":733,"phases":734,"primaryCompletion":735,"completion":735,"start":736,"enrollment":737,"conditions":738,"interventions":740},"NCT04224051","Metformin for Abdominal Aortic Aneurysm Growth Inhibition","UNKNOWN",[90],"2026-01","2020-02-12",500,[739],"Abdominal Aortic Aneurysm",[722],{"trials":742,"activeCount":100},[],{"trials":744,"activeCount":100},[745],{"nctId":746,"briefTitle":747,"status":586,"phases":748,"primaryCompletion":749,"completion":749,"start":750,"enrollment":751,"conditions":752,"interventions":754},"NCT03982381","SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes",[92],"2026-01-31","2019-09-05",2067,[753],"Type 2 Diabetes",[722,755],"Dapagliflozin 10 MG",{"trials":757,"activeCount":100},[],{"intervention":759,"totalTrials":654,"cells":760},"levodopa\u002Fcarbidopa",{"EARLY_PHASE1":761,"PHASE1":763,"PHASE2":765,"PHASE3":767,"PHASE4":769,"NA":792},{"trials":762,"activeCount":100},[],{"trials":764,"activeCount":100},[],{"trials":766,"activeCount":100},[],{"trials":768,"activeCount":100},[],{"trials":770,"activeCount":100},[771,782],{"nctId":772,"briefTitle":773,"status":586,"phases":774,"primaryCompletion":775,"completion":775,"start":776,"enrollment":20,"conditions":777,"interventions":779},"NCT00906828","Pharmacokinetics of Levodopa\u002FCarbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors",[92],"2009-11","2008-10",[778],"Parkinson Disease",[759,780,781],"entacapone","tolcapone",{"nctId":783,"briefTitle":784,"status":586,"phases":785,"primaryCompletion":786,"completion":786,"start":787,"enrollment":788,"conditions":789,"interventions":791},"NCT00888186","Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics",[92],"2008-05","2008-02",5,[778,790],"Dyskinesias",[759],{"trials":793,"activeCount":100},[],{"intervention":683,"totalTrials":96,"cells":795},{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":802,"PHASE4":804,"NA":810},{"trials":797,"activeCount":100},[],{"trials":799,"activeCount":100},[],{"trials":801,"activeCount":100},[],{"trials":803,"activeCount":100},[],{"trials":805,"activeCount":100},[806],{"nctId":675,"briefTitle":676,"status":586,"phases":807,"primaryCompletion":678,"completion":678,"start":286,"enrollment":679,"conditions":808,"interventions":809},[92],[681],[653,683,684],{"trials":811,"activeCount":100},[],{"intervention":684,"totalTrials":96,"cells":813},{"EARLY_PHASE1":814,"PHASE1":816,"PHASE2":818,"PHASE3":820,"PHASE4":822,"NA":828},{"trials":815,"activeCount":100},[],{"trials":817,"activeCount":100},[],{"trials":819,"activeCount":100},[],{"trials":821,"activeCount":100},[],{"trials":823,"activeCount":100},[824],{"nctId":675,"briefTitle":676,"status":586,"phases":825,"primaryCompletion":678,"completion":678,"start":286,"enrollment":679,"conditions":826,"interventions":827},[92],[681],[653,683,684],{"trials":829,"activeCount":100},[],{"intervention":831,"totalTrials":96,"cells":832},"Zestril®",{"EARLY_PHASE1":833,"PHASE1":835,"PHASE2":837,"PHASE3":839,"PHASE4":841,"NA":858},{"trials":834,"activeCount":100},[],{"trials":836,"activeCount":100},[],{"trials":838,"activeCount":100},[],{"trials":840,"activeCount":100},[],{"trials":842,"activeCount":100},[843],{"nctId":844,"briefTitle":845,"status":586,"phases":846,"primaryCompletion":847,"completion":847,"start":848,"enrollment":849,"conditions":850,"interventions":852},"NCT02774460","The Precision Hypertension Care Study",[92],"2021-06-11","2017-02-20",280,[851],"Hypertension",[831,853,854,855,856,857],"Atacand®","Norvasc®","Hydrochlorthiazide®","Treatment X","Treatment Y",{"trials":859,"activeCount":100},[],{"intervention":853,"totalTrials":96,"cells":861},{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":868,"PHASE4":870,"NA":876},{"trials":863,"activeCount":100},[],{"trials":865,"activeCount":100},[],{"trials":867,"activeCount":100},[],{"trials":869,"activeCount":100},[],{"trials":871,"activeCount":100},[872],{"nctId":844,"briefTitle":845,"status":586,"phases":873,"primaryCompletion":847,"completion":847,"start":848,"enrollment":849,"conditions":874,"interventions":875},[92],[851],[831,853,854,855,856,857],{"trials":877,"activeCount":100},[],{"intervention":854,"totalTrials":96,"cells":879},{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":886,"PHASE4":888,"NA":894},{"trials":881,"activeCount":100},[],{"trials":883,"activeCount":100},[],{"trials":885,"activeCount":100},[],{"trials":887,"activeCount":100},[],{"trials":889,"activeCount":100},[890],{"nctId":844,"briefTitle":845,"status":586,"phases":891,"primaryCompletion":847,"completion":847,"start":848,"enrollment":849,"conditions":892,"interventions":893},[92],[851],[831,853,854,855,856,857],{"trials":895,"activeCount":100},[],{"intervention":855,"totalTrials":96,"cells":897},{"EARLY_PHASE1":898,"PHASE1":900,"PHASE2":902,"PHASE3":904,"PHASE4":906,"NA":912},{"trials":899,"activeCount":100},[],{"trials":901,"activeCount":100},[],{"trials":903,"activeCount":100},[],{"trials":905,"activeCount":100},[],{"trials":907,"activeCount":100},[908],{"nctId":844,"briefTitle":845,"status":586,"phases":909,"primaryCompletion":847,"completion":847,"start":848,"enrollment":849,"conditions":910,"interventions":911},[92],[851],[831,853,854,855,856,857],{"trials":913,"activeCount":100},[],{"intervention":856,"totalTrials":96,"cells":915},{"EARLY_PHASE1":916,"PHASE1":918,"PHASE2":920,"PHASE3":922,"PHASE4":924,"NA":930},{"trials":917,"activeCount":100},[],{"trials":919,"activeCount":100},[],{"trials":921,"activeCount":100},[],{"trials":923,"activeCount":100},[],{"trials":925,"activeCount":100},[926],{"nctId":844,"briefTitle":845,"status":586,"phases":927,"primaryCompletion":847,"completion":847,"start":848,"enrollment":849,"conditions":928,"interventions":929},[92],[851],[831,853,854,855,856,857],{"trials":931,"activeCount":100},[],{"intervention":857,"totalTrials":96,"cells":933},{"EARLY_PHASE1":934,"PHASE1":936,"PHASE2":938,"PHASE3":940,"PHASE4":942,"NA":948},{"trials":935,"activeCount":100},[],{"trials":937,"activeCount":100},[],{"trials":939,"activeCount":100},[],{"trials":941,"activeCount":100},[],{"trials":943,"activeCount":100},[944],{"nctId":844,"briefTitle":845,"status":586,"phases":945,"primaryCompletion":847,"completion":847,"start":848,"enrollment":849,"conditions":946,"interventions":947},[92],[851],[831,853,854,855,856,857],{"trials":949,"activeCount":100},[],{"intervention":951,"totalTrials":96,"cells":952},"Triamcinolone hexacetonide",{"EARLY_PHASE1":953,"PHASE1":955,"PHASE2":957,"PHASE3":959,"PHASE4":961,"NA":974},{"trials":954,"activeCount":100},[],{"trials":956,"activeCount":100},[],{"trials":958,"activeCount":100},[],{"trials":960,"activeCount":100},[],{"trials":962,"activeCount":100},[963],{"nctId":964,"briefTitle":965,"status":733,"phases":966,"primaryCompletion":967,"completion":968,"start":969,"enrollment":970,"conditions":971,"interventions":973},"NCT02437461","Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis",[92],"2017-09-30","2018-06-20","2015-04",159,[972],"Arthritis of the Knee",[951],{"trials":975,"activeCount":100},[],{"intervention":755,"totalTrials":96,"cells":977},{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":982,"PHASE3":984,"PHASE4":986,"NA":992},{"trials":979,"activeCount":100},[],{"trials":981,"activeCount":100},[],{"trials":983,"activeCount":100},[],{"trials":985,"activeCount":100},[],{"trials":987,"activeCount":100},[988],{"nctId":746,"briefTitle":747,"status":586,"phases":989,"primaryCompletion":749,"completion":749,"start":750,"enrollment":751,"conditions":990,"interventions":991},[92],[753],[722,755],{"trials":993,"activeCount":100},[],{"intervention":995,"totalTrials":96,"cells":996},"Beta blocker",{"EARLY_PHASE1":997,"PHASE1":999,"PHASE2":1001,"PHASE3":1003,"PHASE4":1005,"NA":1021},{"trials":998,"activeCount":100},[],{"trials":1000,"activeCount":100},[],{"trials":1002,"activeCount":100},[],{"trials":1004,"activeCount":100},[],{"trials":1006,"activeCount":100},[1007],{"nctId":1008,"briefTitle":1009,"status":1010,"phases":1011,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":1015,"conditions":1016,"interventions":1018},"NCT03686696","Randomized Evaluation of Beta Blocker and ACEI\u002FARB Treatment in MINOCA Patients - MINOCA-BAT","TERMINATED",[92],"2023-05-31","2023-08-22","2018-12-16",198,[1017],"Myocardial Infarction With Non-obstructive Coronary Arteries",[995,1019,1020],"ACEI","ARB",{"trials":1022,"activeCount":100},[],{"intervention":1019,"totalTrials":96,"cells":1024},{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1031,"PHASE4":1033,"NA":1039},{"trials":1026,"activeCount":100},[],{"trials":1028,"activeCount":100},[],{"trials":1030,"activeCount":100},[],{"trials":1032,"activeCount":100},[],{"trials":1034,"activeCount":100},[1035],{"nctId":1008,"briefTitle":1009,"status":1010,"phases":1036,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":1015,"conditions":1037,"interventions":1038},[92],[1017],[995,1019,1020],{"trials":1040,"activeCount":100},[],{"intervention":1020,"totalTrials":96,"cells":1042},{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1049,"PHASE4":1051,"NA":1057},{"trials":1044,"activeCount":100},[],{"trials":1046,"activeCount":100},[],{"trials":1048,"activeCount":100},[],{"trials":1050,"activeCount":100},[],{"trials":1052,"activeCount":100},[1053],{"nctId":1008,"briefTitle":1009,"status":1010,"phases":1054,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":1015,"conditions":1055,"interventions":1056},[92],[1017],[995,1019,1020],{"trials":1058,"activeCount":100},[],{"intervention":780,"totalTrials":96,"cells":1060},{"EARLY_PHASE1":1061,"PHASE1":1063,"PHASE2":1065,"PHASE3":1067,"PHASE4":1069,"NA":1075},{"trials":1062,"activeCount":100},[],{"trials":1064,"activeCount":100},[],{"trials":1066,"activeCount":100},[],{"trials":1068,"activeCount":100},[],{"trials":1070,"activeCount":100},[1071],{"nctId":772,"briefTitle":773,"status":586,"phases":1072,"primaryCompletion":775,"completion":775,"start":776,"enrollment":20,"conditions":1073,"interventions":1074},[92],[778],[759,780,781],{"trials":1076,"activeCount":100},[],{"intervention":781,"totalTrials":96,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1085,"PHASE4":1087,"NA":1093},{"trials":1080,"activeCount":100},[],{"trials":1082,"activeCount":100},[],{"trials":1084,"activeCount":100},[],{"trials":1086,"activeCount":100},[],{"trials":1088,"activeCount":100},[1089],{"nctId":772,"briefTitle":773,"status":586,"phases":1090,"primaryCompletion":775,"completion":775,"start":776,"enrollment":20,"conditions":1091,"interventions":1092},[92],[778],[759,780,781],{"trials":1094,"activeCount":100},[],{"intervention":1096,"totalTrials":96,"cells":1097},"bivalirudin",{"EARLY_PHASE1":1098,"PHASE1":1100,"PHASE2":1102,"PHASE3":1104,"PHASE4":1106,"NA":1120},{"trials":1099,"activeCount":100},[],{"trials":1101,"activeCount":100},[],{"trials":1103,"activeCount":100},[],{"trials":1105,"activeCount":100},[],{"trials":1107,"activeCount":100},[1108],{"nctId":1109,"briefTitle":1110,"status":586,"phases":1111,"primaryCompletion":1112,"completion":1112,"start":1113,"enrollment":1114,"conditions":1115,"interventions":1118},"NCT02311231","Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART",[92],"2017-03","2014-06",6012,[1116,1117],"ST-segment Elevation Myocardial Infarction","Non ST-segment Elevation Myocardial Infarction",[1096,1119],"Heparin",{"trials":1121,"activeCount":100},[],{"intervention":1119,"totalTrials":96,"cells":1123},{"EARLY_PHASE1":1124,"PHASE1":1126,"PHASE2":1128,"PHASE3":1130,"PHASE4":1132,"NA":1138},{"trials":1125,"activeCount":100},[],{"trials":1127,"activeCount":100},[],{"trials":1129,"activeCount":100},[],{"trials":1131,"activeCount":100},[],{"trials":1133,"activeCount":100},[1134],{"nctId":1109,"briefTitle":1110,"status":586,"phases":1135,"primaryCompletion":1112,"completion":1112,"start":1113,"enrollment":1114,"conditions":1136,"interventions":1137},[92],[1116,1117],[1096,1119],{"trials":1139,"activeCount":100},[],{"intervention":1141,"totalTrials":96,"cells":1142},"Phenoxymethylpenicillin",{"EARLY_PHASE1":1143,"PHASE1":1145,"PHASE2":1147,"PHASE3":1149,"PHASE4":1151,"NA":1165},{"trials":1144,"activeCount":100},[],{"trials":1146,"activeCount":100},[],{"trials":1148,"activeCount":100},[],{"trials":1150,"activeCount":100},[],{"trials":1152,"activeCount":100},[1153],{"nctId":1154,"briefTitle":1155,"status":586,"phases":1156,"primaryCompletion":1157,"completion":1157,"start":1158,"enrollment":1159,"conditions":1160,"interventions":1162},"NCT04084106","Effects of Phenoximethylpenicillin, Amoxicillin and Amoxicillin-clavulanic Acid on the Gut Microbiota",[92],"2022-11-11","2019-09-10",104,[1161],"Infectious Disease",[1141,1163,1164],"Amoxicillin","Amoxicillin-clavulanic acid",{"trials":1166,"activeCount":100},[],{"intervention":1163,"totalTrials":96,"cells":1168},{"EARLY_PHASE1":1169,"PHASE1":1171,"PHASE2":1173,"PHASE3":1175,"PHASE4":1177,"NA":1183},{"trials":1170,"activeCount":100},[],{"trials":1172,"activeCount":100},[],{"trials":1174,"activeCount":100},[],{"trials":1176,"activeCount":100},[],{"trials":1178,"activeCount":100},[1179],{"nctId":1154,"briefTitle":1155,"status":586,"phases":1180,"primaryCompletion":1157,"completion":1157,"start":1158,"enrollment":1159,"conditions":1181,"interventions":1182},[92],[1161],[1141,1163,1164],{"trials":1184,"activeCount":100},[],{"intervention":1164,"totalTrials":96,"cells":1186},{"EARLY_PHASE1":1187,"PHASE1":1189,"PHASE2":1191,"PHASE3":1193,"PHASE4":1195,"NA":1201},{"trials":1188,"activeCount":100},[],{"trials":1190,"activeCount":100},[],{"trials":1192,"activeCount":100},[],{"trials":1194,"activeCount":100},[],{"trials":1196,"activeCount":100},[1197],{"nctId":1154,"briefTitle":1155,"status":586,"phases":1198,"primaryCompletion":1157,"completion":1157,"start":1158,"enrollment":1159,"conditions":1199,"interventions":1200},[92],[1161],[1141,1163,1164],{"trials":1202,"activeCount":100},[],{"intervention":1204,"totalTrials":96,"cells":1205},"Methylprednisolone",{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1212,"PHASE4":1214,"NA":1228},{"trials":1207,"activeCount":100},[],{"trials":1209,"activeCount":100},[],{"trials":1211,"activeCount":100},[],{"trials":1213,"activeCount":100},[],{"trials":1215,"activeCount":100},[1216],{"nctId":1217,"briefTitle":1218,"status":586,"phases":1219,"primaryCompletion":1220,"completion":1220,"start":1221,"enrollment":1222,"conditions":1223,"interventions":1226},"NCT01995019","Arthralgia of the Temporomandibular Joint. Pain Relief Following One Intra-articular Injection of Methylprednisolone",[92],"2017-03-15","2013-12-10",56,[1224,1225],"Arthralgia","TMJ",[1204,1227],"Physiologic saline",{"trials":1229,"activeCount":100},[],{"intervention":1227,"totalTrials":96,"cells":1231},{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1236,"PHASE3":1238,"PHASE4":1240,"NA":1246},{"trials":1233,"activeCount":100},[],{"trials":1235,"activeCount":100},[],{"trials":1237,"activeCount":100},[],{"trials":1239,"activeCount":100},[],{"trials":1241,"activeCount":100},[1242],{"nctId":1217,"briefTitle":1218,"status":586,"phases":1243,"primaryCompletion":1220,"completion":1220,"start":1221,"enrollment":1222,"conditions":1244,"interventions":1245},[92],[1224,1225],[1204,1227],{"trials":1247,"activeCount":100},[],{"intervention":1249,"totalTrials":96,"cells":1250},"Prednisolone + placebo",{"EARLY_PHASE1":1251,"PHASE1":1253,"PHASE2":1255,"PHASE3":1257,"PHASE4":1259,"NA":1273},{"trials":1252,"activeCount":100},[],{"trials":1254,"activeCount":100},[],{"trials":1256,"activeCount":100},[],{"trials":1258,"activeCount":100},[],{"trials":1260,"activeCount":100},[1261],{"nctId":1262,"briefTitle":1263,"status":586,"phases":1264,"primaryCompletion":1265,"completion":1265,"start":1266,"enrollment":1267,"conditions":1268,"interventions":1270},"NCT00510263","Scandinavian Bell's Palsy Study",[92],"2007-09","2001-05",839,[1269],"Bell's Palsy",[1249,1271,1272],"Valaciclovir + placebo","Prednisolone + valaciclovir",{"trials":1274,"activeCount":100},[],{"intervention":1271,"totalTrials":96,"cells":1276},{"EARLY_PHASE1":1277,"PHASE1":1279,"PHASE2":1281,"PHASE3":1283,"PHASE4":1285,"NA":1291},{"trials":1278,"activeCount":100},[],{"trials":1280,"activeCount":100},[],{"trials":1282,"activeCount":100},[],{"trials":1284,"activeCount":100},[],{"trials":1286,"activeCount":100},[1287],{"nctId":1262,"briefTitle":1263,"status":586,"phases":1288,"primaryCompletion":1265,"completion":1265,"start":1266,"enrollment":1267,"conditions":1289,"interventions":1290},[92],[1269],[1249,1271,1272],{"trials":1292,"activeCount":100},[],{"intervention":1272,"totalTrials":96,"cells":1294},{"EARLY_PHASE1":1295,"PHASE1":1297,"PHASE2":1299,"PHASE3":1301,"PHASE4":1303,"NA":1309},{"trials":1296,"activeCount":100},[],{"trials":1298,"activeCount":100},[],{"trials":1300,"activeCount":100},[],{"trials":1302,"activeCount":100},[],{"trials":1304,"activeCount":100},[1305],{"nctId":1262,"briefTitle":1263,"status":586,"phases":1306,"primaryCompletion":1265,"completion":1265,"start":1266,"enrollment":1267,"conditions":1307,"interventions":1308},[92],[1269],[1249,1271,1272],{"trials":1310,"activeCount":100},[],{"intervention":1312,"totalTrials":96,"cells":1313},"Systemic chemotherapy alone",{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1318,"PHASE3":1320,"PHASE4":1333,"NA":1335},{"trials":1315,"activeCount":100},[],{"trials":1317,"activeCount":100},[],{"trials":1319,"activeCount":100},[],{"trials":1321,"activeCount":100},[1322],{"nctId":1323,"briefTitle":1324,"status":586,"phases":1325,"primaryCompletion":1326,"completion":1327,"start":1328,"enrollment":1329,"conditions":1330,"interventions":1332},"NCT01524094","Cytoreduction and Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis",[91],"2010-12","2012-01","2003-06",49,[1331],"Colorectal Peritoneal Carcinomatosis",[1312],{"trials":1334,"activeCount":100},[],{"trials":1336,"activeCount":100},[],{"intervention":669,"totalTrials":654,"cells":1338},{"EARLY_PHASE1":1339,"PHASE1":1341,"PHASE2":1343,"PHASE3":1358,"PHASE4":1360,"NA":1362},{"trials":1340,"activeCount":100},[],{"trials":1342,"activeCount":100},[],{"trials":1344,"activeCount":100},[1345,1354],{"nctId":1346,"briefTitle":1347,"status":586,"phases":1348,"primaryCompletion":1349,"completion":1350,"start":713,"enrollment":1351,"conditions":1352,"interventions":1353},"NCT02794402","Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI",[90],"2016-09","2016-11",44,[16],[669],{"nctId":663,"briefTitle":664,"status":586,"phases":1355,"primaryCompletion":286,"completion":286,"start":666,"enrollment":114,"conditions":1356,"interventions":1357},[90],[16],[653,669],{"trials":1359,"activeCount":100},[],{"trials":1361,"activeCount":100},[],{"trials":1363,"activeCount":100},[],{"intervention":1365,"totalTrials":654,"cells":1366},"AdCD40L",{"EARLY_PHASE1":1367,"PHASE1":1369,"PHASE2":1371,"PHASE3":1392,"PHASE4":1394,"NA":1396},{"trials":1368,"activeCount":100},[],{"trials":1370,"activeCount":100},[],{"trials":1372,"activeCount":100},[1373,1383],{"nctId":1374,"briefTitle":1375,"status":586,"phases":1376,"primaryCompletion":1377,"completion":1377,"start":1378,"enrollment":1379,"conditions":1380,"interventions":1382},"NCT00891748","Safety Study on AdCD40L Gene Therapy for Bladder Cancer",[89,90],"2009-10","2006-11",12,[1381],"Bladder Cancer",[1365],{"nctId":1384,"briefTitle":1385,"status":586,"phases":1386,"primaryCompletion":1387,"completion":1387,"start":1388,"enrollment":715,"conditions":1389,"interventions":1391},"NCT01455259","Phase I\u002FIIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors",[89,90],"2016-01","2011-09",[1390],"Malignant Melanoma",[1365],{"trials":1393,"activeCount":100},[],{"trials":1395,"activeCount":100},[],{"trials":1397,"activeCount":100},[],{"intervention":1399,"totalTrials":96,"cells":1400},"autologous mesenchymal stem cell transplantation",{"EARLY_PHASE1":1401,"PHASE1":1403,"PHASE2":1405,"PHASE3":1416,"PHASE4":1418,"NA":1420},{"trials":1402,"activeCount":100},[],{"trials":1404,"activeCount":100},[],{"trials":1406,"activeCount":100},[1407],{"nctId":1408,"briefTitle":1409,"status":1010,"phases":1410,"primaryCompletion":1411,"completion":1411,"start":1412,"enrollment":20,"conditions":1413,"interventions":1415},"NCT02057211","Mesenchymal Stem Cells to Intervene in the Development of Type 1 Diabetes: a Blinded Randomized Study",[90],"2017-11","2014-04",[1414],"Type 1 Diabetes Mellitus",[1399],{"trials":1417,"activeCount":100},[],{"trials":1419,"activeCount":100},[],{"trials":1421,"activeCount":100},[],{"intervention":1423,"totalTrials":96,"cells":1424},"Azithromycin Monohydrate",{"EARLY_PHASE1":1425,"PHASE1":1427,"PHASE2":1429,"PHASE3":1449,"PHASE4":1451,"NA":1453},{"trials":1426,"activeCount":100},[],{"trials":1428,"activeCount":100},[],{"trials":1430,"activeCount":100},[1431],{"nctId":1432,"briefTitle":1433,"status":733,"phases":1434,"primaryCompletion":1435,"completion":1435,"start":1436,"enrollment":423,"conditions":1437,"interventions":1447},"NCT03682640","Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes",[90],"2021-12-31","2018-09",[1438,1439,1440,1441,1442,1443,1444,1414,1445,1446],"Diabetes Mellitus, Type 1","Diabetes Mellitus","Metabolic Disease","Glucose Metabolism Disorders","Endocrine System Diseases","Juvenile Diabetes","Insulin Dependent Diabetes","Inflammation","Diet Modification",[1423,1448],"Insulin Lispro",{"trials":1450,"activeCount":100},[],{"trials":1452,"activeCount":100},[],{"trials":1454,"activeCount":100},[],{"intervention":1448,"totalTrials":96,"cells":1456},{"EARLY_PHASE1":1457,"PHASE1":1459,"PHASE2":1461,"PHASE3":1467,"PHASE4":1469,"NA":1471},{"trials":1458,"activeCount":100},[],{"trials":1460,"activeCount":100},[],{"trials":1462,"activeCount":100},[1463],{"nctId":1432,"briefTitle":1433,"status":733,"phases":1464,"primaryCompletion":1435,"completion":1435,"start":1436,"enrollment":423,"conditions":1465,"interventions":1466},[90],[1438,1439,1440,1441,1442,1443,1444,1414,1445,1446],[1423,1448],{"trials":1468,"activeCount":100},[],{"trials":1470,"activeCount":100},[],{"trials":1472,"activeCount":100},[],{"intervention":1474,"totalTrials":96,"cells":1475},"Electrochemotherapy",{"EARLY_PHASE1":1476,"PHASE1":1478,"PHASE2":1480,"PHASE3":1492,"PHASE4":1494,"NA":1496},{"trials":1477,"activeCount":100},[],{"trials":1479,"activeCount":100},[],{"trials":1481,"activeCount":100},[1482],{"nctId":1483,"briefTitle":1484,"status":1485,"phases":1486,"primaryCompletion":666,"completion":1487,"start":1488,"enrollment":100,"conditions":1489,"interventions":1491},"NCT01479946","Electrochemotherapy For The Treatment Of Breast Cancer That Has Spread to the Skin","WITHDRAWN",[90],"2015-06","2011-10",[27,1490],"Skin Metastases",[1474],{"trials":1493,"activeCount":100},[],{"trials":1495,"activeCount":100},[],{"trials":1497,"activeCount":100},[],{"intervention":1499,"totalTrials":96,"cells":1500},"Acetazolamide",{"EARLY_PHASE1":1501,"PHASE1":1503,"PHASE2":1505,"PHASE3":1517,"PHASE4":1519,"NA":1521},{"trials":1502,"activeCount":100},[],{"trials":1504,"activeCount":100},[],{"trials":1506,"activeCount":100},[1507],{"nctId":1508,"briefTitle":1509,"status":586,"phases":1510,"primaryCompletion":1511,"completion":1512,"start":1513,"enrollment":114,"conditions":1514,"interventions":1516},"NCT04975269","Acetazolamide Trial in Normal Pressure Hydrocephalus",[90],"2024-11-18","2026-04-21","2022-02-17",[1515],"Idiopathic Normal Pressure Hydrocephalus (INPH)",[1499],{"trials":1518,"activeCount":100},[],{"trials":1520,"activeCount":100},[],{"trials":1522,"activeCount":100},[],{"intervention":1524,"totalTrials":96,"cells":1525},"Ticagrelor",{"EARLY_PHASE1":1526,"PHASE1":1528,"PHASE2":1530,"PHASE3":1542,"PHASE4":1544,"NA":1546},{"trials":1527,"activeCount":100},[],{"trials":1529,"activeCount":100},[],{"trials":1531,"activeCount":100},[1532],{"nctId":1533,"briefTitle":1534,"status":586,"phases":1535,"primaryCompletion":1536,"completion":1537,"start":1538,"enrollment":1539,"conditions":1540,"interventions":1541},"NCT02070653","The Efficacy of Ticagrelor on Abdominal Aortic Aneurysm (AAA) Expansion",[90],"2016-07","2017-07","2014-03",145,[739],[1524],{"trials":1543,"activeCount":100},[],{"trials":1545,"activeCount":100},[],{"trials":1547,"activeCount":100},[],{"intervention":1549,"totalTrials":96,"cells":1550},"imatinib and pegylated interferon",{"EARLY_PHASE1":1551,"PHASE1":1553,"PHASE2":1555,"PHASE3":1568,"PHASE4":1570,"NA":1572},{"trials":1552,"activeCount":100},[],{"trials":1554,"activeCount":100},[],{"trials":1556,"activeCount":100},[1557],{"nctId":1558,"briefTitle":1559,"status":586,"phases":1560,"primaryCompletion":1561,"completion":775,"start":1562,"enrollment":1563,"conditions":1564,"interventions":1567},"NCT01227356","A Study Comparing Imatinib and Imatinib\u002FPegylated Interferon in Chronic Myeloid Leukemia",[90],"2009-03","2004-09",112,[1565,1566],"Health Care Quality","Health Care Evaluation",[1549],{"trials":1569,"activeCount":100},[],{"trials":1571,"activeCount":100},[],{"trials":1573,"activeCount":100},[],{"intervention":1575,"totalTrials":96,"cells":1576},"Eculizumab",{"EARLY_PHASE1":1577,"PHASE1":1579,"PHASE2":1581,"PHASE3":1592,"PHASE4":1594,"NA":1596},{"trials":1578,"activeCount":100},[],{"trials":1580,"activeCount":100},[],{"trials":1582,"activeCount":100},[1583],{"nctId":1584,"briefTitle":1585,"status":586,"phases":1586,"primaryCompletion":1587,"completion":1588,"start":1589,"enrollment":577,"conditions":1590,"interventions":1591},"NCT02727608","Complement Inhibitor Eculizumab in Clinical Islet Transplantation",[90],"2018-05","2018-06","2016-05-15",[1439],[1575],{"trials":1593,"activeCount":100},[],{"trials":1595,"activeCount":100},[],{"trials":1597,"activeCount":100},[],{"intervention":1599,"totalTrials":96,"cells":1600},"Aprepitant",{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1605,"PHASE3":1618,"PHASE4":1620,"NA":1622},{"trials":1602,"activeCount":100},[],{"trials":1604,"activeCount":100},[],{"trials":1606,"activeCount":100},[1607],{"nctId":1608,"briefTitle":1609,"status":586,"phases":1610,"primaryCompletion":1611,"completion":1611,"start":1612,"enrollment":1613,"conditions":1614,"interventions":1617},"NCT01101529","Treatment of Chemotherapy-induced Nausea and Vomiting",[90],"2012-12","2010-05",90,[1615,1616],"Nausea","Vomiting",[1599],{"trials":1619,"activeCount":100},[],{"trials":1621,"activeCount":100},[],{"trials":1623,"activeCount":100},[],{"intervention":1625,"totalTrials":96,"cells":1626},"radiotherapy, capecitabine, oxaliplatin",{"EARLY_PHASE1":1627,"PHASE1":1629,"PHASE2":1631,"PHASE3":1643,"PHASE4":1645,"NA":1647},{"trials":1628,"activeCount":100},[],{"trials":1630,"activeCount":100},[],{"trials":1632,"activeCount":100},[1633],{"nctId":1634,"briefTitle":1635,"status":733,"phases":1636,"primaryCompletion":1637,"completion":1638,"start":1639,"enrollment":849,"conditions":1640,"interventions":1642},"NCT03729687","Short Course Radiation Therapy Followed by Pre-operative Chemotherapy and Surgery in High-risk Rectal Cancer",[90],"2020-05-30","2025-06-30","2016-07-04",[1641],"Rectal Cancer",[1625],{"trials":1644,"activeCount":100},[],{"trials":1646,"activeCount":100},[],{"trials":1648,"activeCount":100},[],{"intervention":1650,"totalTrials":96,"cells":1651},"Multimodal treatment",{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1656,"PHASE3":1667,"PHASE4":1669,"NA":1671},{"trials":1653,"activeCount":100},[],{"trials":1655,"activeCount":100},[],{"trials":1657,"activeCount":100},[1658],{"nctId":1659,"briefTitle":1660,"status":586,"phases":1661,"primaryCompletion":1561,"completion":1561,"start":1662,"enrollment":308,"conditions":1663,"interventions":1666},"NCT01379482","Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer",[90],"2005-01",[1664,1665],"Peritoneal Carcinomatosis","Gastric Cancer",[1650],{"trials":1668,"activeCount":100},[],{"trials":1670,"activeCount":100},[],{"trials":1672,"activeCount":100},[],{"intervention":1674,"totalTrials":96,"cells":1675},"Autologous 3rd generation CD19-targeting CAR T cells",{"EARLY_PHASE1":1676,"PHASE1":1678,"PHASE2":1680,"PHASE3":1691,"PHASE4":1693,"NA":1695},{"trials":1677,"activeCount":100},[],{"trials":1679,"activeCount":100},[],{"trials":1681,"activeCount":100},[1682],{"nctId":1683,"briefTitle":1684,"status":586,"phases":1685,"primaryCompletion":1686,"completion":1686,"start":1412,"enrollment":679,"conditions":1687,"interventions":1690},"NCT02132624","CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I\u002FIIa Trial.",[89,90],"2017-05-31",[1688,1689],"B Cell Lymphoma","B Cell Leukemia",[1674],{"trials":1692,"activeCount":100},[],{"trials":1694,"activeCount":100},[],{"trials":1696,"activeCount":100},[],{"intervention":1698,"totalTrials":96,"cells":1699},"PPSV23, Act-HIB",{"EARLY_PHASE1":1700,"PHASE1":1702,"PHASE2":1704,"PHASE3":1717,"PHASE4":1719,"NA":1721},{"trials":1701,"activeCount":100},[],{"trials":1703,"activeCount":100},[],{"trials":1705,"activeCount":100},[1706],{"nctId":1707,"briefTitle":1708,"status":586,"phases":1709,"primaryCompletion":1710,"completion":1711,"start":1712,"enrollment":1713,"conditions":1714,"interventions":1716},"NCT02806284","Pneumococci and Hib Vaccination After Neurotrauma or Neurosurgery",[90],"2008-01","2010-01","2001-01",85,[1715],"Meningitis",[1698],{"trials":1718,"activeCount":100},[],{"trials":1720,"activeCount":100},[],{"trials":1722,"activeCount":100},[],{"intervention":1724,"totalTrials":96,"cells":1725},"CAR T cells",{"EARLY_PHASE1":1726,"PHASE1":1728,"PHASE2":1730,"PHASE3":1742,"PHASE4":1744,"NA":1746},{"trials":1727,"activeCount":100},[],{"trials":1729,"activeCount":100},[],{"trials":1731,"activeCount":100},[1732],{"nctId":1733,"briefTitle":1734,"status":586,"phases":1735,"primaryCompletion":1736,"completion":1736,"start":1737,"enrollment":591,"conditions":1738,"interventions":1741},"NCT03068416","CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy",[90],"2021-08-19","2017-09-18",[1739,1740],"B-cell Leukemia","B-Cell Lymphoma",[1724],{"trials":1743,"activeCount":100},[],{"trials":1745,"activeCount":100},[],{"trials":1747,"activeCount":100},[],{"intervention":1749,"totalTrials":96,"cells":1750},"gabapentin and venlafaxine",{"EARLY_PHASE1":1751,"PHASE1":1753,"PHASE2":1755,"PHASE3":1767,"PHASE4":1769,"NA":1771},{"trials":1752,"activeCount":100},[],{"trials":1754,"activeCount":100},[],{"trials":1756,"activeCount":100},[1757],{"nctId":1758,"briefTitle":1759,"status":586,"phases":1760,"primaryCompletion":1761,"completion":1388,"start":1762,"enrollment":715,"conditions":1763,"interventions":1765},"NCT00967707","Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain",[90],"2011-04","2009-08",[1764],"Post-traumatic Neuropathic Pain",[1749,1766],"gabapentin and donepezil",{"trials":1768,"activeCount":100},[],{"trials":1770,"activeCount":100},[],{"trials":1772,"activeCount":100},[],{"intervention":1766,"totalTrials":96,"cells":1774},{"EARLY_PHASE1":1775,"PHASE1":1777,"PHASE2":1779,"PHASE3":1785,"PHASE4":1787,"NA":1789},{"trials":1776,"activeCount":100},[],{"trials":1778,"activeCount":100},[],{"trials":1780,"activeCount":100},[1781],{"nctId":1758,"briefTitle":1759,"status":586,"phases":1782,"primaryCompletion":1761,"completion":1388,"start":1762,"enrollment":715,"conditions":1783,"interventions":1784},[90],[1764],[1749,1766],{"trials":1786,"activeCount":100},[],{"trials":1788,"activeCount":100},[],{"trials":1790,"activeCount":100},[],{"intervention":1792,"totalTrials":96,"cells":1793},"ACHIM",{"EARLY_PHASE1":1794,"PHASE1":1796,"PHASE2":1798,"PHASE3":1809,"PHASE4":1811,"NA":1813},{"trials":1795,"activeCount":100},[],{"trials":1797,"activeCount":100},[],{"trials":1799,"activeCount":100},[1800],{"nctId":1801,"briefTitle":1802,"status":733,"phases":1803,"primaryCompletion":1804,"completion":1804,"start":1805,"enrollment":114,"conditions":1806,"interventions":1808},"NCT02857257","Transplantation of Anaerobic Cultured Human Intestinal Microbiota in Irritable Bowel Syndrome",[90],"2018-12","2015-01",[1807],"Irritable Bowel Syndrome",[1792],{"trials":1810,"activeCount":100},[],{"trials":1812,"activeCount":100},[],{"trials":1814,"activeCount":100},[],{"intervention":1816,"totalTrials":96,"cells":1817},"Dysport®",{"EARLY_PHASE1":1818,"PHASE1":1820,"PHASE2":1822,"PHASE3":1832,"PHASE4":1834,"NA":1836},{"trials":1819,"activeCount":100},[],{"trials":1821,"activeCount":100},[],{"trials":1823,"activeCount":100},[1824],{"nctId":1825,"briefTitle":1826,"status":733,"phases":1827,"primaryCompletion":1611,"completion":1611,"start":1828,"enrollment":391,"conditions":1829,"interventions":1831},"NCT00936533","Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita",[90],"2009-05",[1830],"Epidermolysis Bullosa Simplex",[1816],{"trials":1833,"activeCount":100},[],{"trials":1835,"activeCount":100},[],{"trials":1837,"activeCount":100},[],{"intervention":1839,"totalTrials":96,"cells":1840},"pVAXrcPSAv53l",{"EARLY_PHASE1":1841,"PHASE1":1843,"PHASE2":1845,"PHASE3":1855,"PHASE4":1857,"NA":1859},{"trials":1842,"activeCount":100},[],{"trials":1844,"activeCount":100},[],{"trials":1846,"activeCount":100},[1847],{"nctId":1848,"briefTitle":1849,"status":586,"phases":1850,"primaryCompletion":1851,"completion":1851,"start":1852,"enrollment":679,"conditions":1853,"interventions":1854},"NCT00859729","Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer",[89,90],"2011-11","2008-12",[532],[1839],{"trials":1856,"activeCount":100},[],{"trials":1858,"activeCount":100},[],{"trials":1860,"activeCount":100},[],{"intervention":1862,"totalTrials":96,"cells":1863},"Clopidogrel",{"EARLY_PHASE1":1864,"PHASE1":1866,"PHASE2":1868,"PHASE3":1884,"PHASE4":1886,"NA":1888},{"trials":1865,"activeCount":100},[],{"trials":1867,"activeCount":100},[],{"trials":1869,"activeCount":100},[1870],{"nctId":1871,"briefTitle":1872,"status":586,"phases":1873,"primaryCompletion":1874,"completion":1874,"start":1875,"enrollment":1876,"conditions":1877,"interventions":1883},"NCT00914368","Tailoring Of Platelet Inhibition to Avoid Stent Thrombosis",[90],"2010-03","2009-01",450,[1878,1879,1880,1881,1882],"Coronary Artery Disease","Myocardial Infarction","Stent Thrombosis","Heart Diseases","Acute Coronary Syndrome",[1862],{"trials":1885,"activeCount":100},[],{"trials":1887,"activeCount":100},[],{"trials":1889,"activeCount":100},[],{"intervention":1891,"totalTrials":96,"cells":1892},"GLP-1",{"EARLY_PHASE1":1893,"PHASE1":1895,"PHASE2":1907,"PHASE3":1909,"PHASE4":1911,"NA":1913},{"trials":1894,"activeCount":100},[],{"trials":1896,"activeCount":100},[1897],{"nctId":1898,"briefTitle":1899,"status":586,"phases":1900,"primaryCompletion":1901,"completion":1901,"start":1902,"enrollment":1379,"conditions":1903,"interventions":1905},"NCT02731664","GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans",[89],"2017-08","2012-09",[1904],"Functional Gastrointestinal Disorders",[1891,1906],"Intravenous saline",{"trials":1908,"activeCount":100},[],{"trials":1910,"activeCount":100},[],{"trials":1912,"activeCount":100},[],{"trials":1914,"activeCount":100},[],{"intervention":1906,"totalTrials":96,"cells":1916},{"EARLY_PHASE1":1917,"PHASE1":1919,"PHASE2":1925,"PHASE3":1927,"PHASE4":1929,"NA":1931},{"trials":1918,"activeCount":100},[],{"trials":1920,"activeCount":100},[1921],{"nctId":1898,"briefTitle":1899,"status":586,"phases":1922,"primaryCompletion":1901,"completion":1901,"start":1902,"enrollment":1379,"conditions":1923,"interventions":1924},[89],[1904],[1891,1906],{"trials":1926,"activeCount":100},[],{"trials":1928,"activeCount":100},[],{"trials":1930,"activeCount":100},[],{"trials":1932,"activeCount":100},[],{"intervention":1934,"totalTrials":96,"cells":1935},"L-Nitro-Monomethyl-Arginine (LNMMA) 10 mg\u002Fkg IV",{"EARLY_PHASE1":1936,"PHASE1":1938,"PHASE2":1952,"PHASE3":1954,"PHASE4":1956,"NA":1958},{"trials":1937,"activeCount":100},[],{"trials":1939,"activeCount":100},[1940],{"nctId":1941,"briefTitle":1942,"status":586,"phases":1943,"primaryCompletion":1944,"completion":1944,"start":1945,"enrollment":1946,"conditions":1947,"interventions":1950},"NCT02245165","Nitric Oxide Control of Migrating Motor Complex: L-NMMA Effects in Relation to Receptor Blockades",[89],"2014-05","2013-06",29,[1948,1949],"Gastrointestinal Motility Disorder","Disturbance of Salivary Secretion",[1934,1951],"saline",{"trials":1953,"activeCount":100},[],{"trials":1955,"activeCount":100},[],{"trials":1957,"activeCount":100},[],{"trials":1959,"activeCount":100},[],{"intervention":1951,"totalTrials":96,"cells":1961},{"EARLY_PHASE1":1962,"PHASE1":1964,"PHASE2":1970,"PHASE3":1972,"PHASE4":1974,"NA":1976},{"trials":1963,"activeCount":100},[],{"trials":1965,"activeCount":100},[1966],{"nctId":1941,"briefTitle":1942,"status":586,"phases":1967,"primaryCompletion":1944,"completion":1944,"start":1945,"enrollment":1946,"conditions":1968,"interventions":1969},[89],[1948,1949],[1934,1951],{"trials":1971,"activeCount":100},[],{"trials":1973,"activeCount":100},[],{"trials":1975,"activeCount":100},[],{"trials":1977,"activeCount":100},[],{"intervention":1979,"totalTrials":96,"cells":1980},"Mesenchymal Stromal Stem Cells - KI-MSC-PL-205",{"EARLY_PHASE1":1981,"PHASE1":1983,"PHASE2":1995,"PHASE3":1997,"PHASE4":1999,"NA":2001},{"trials":1982,"activeCount":100},[],{"trials":1984,"activeCount":100},[1985],{"nctId":1986,"briefTitle":1987,"status":586,"phases":1988,"primaryCompletion":1989,"completion":422,"start":1990,"enrollment":33,"conditions":1991,"interventions":1994},"NCT04447833","Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome",[89],"2021-01-30","2020-06-17",[1992,1993],"ARDS, Human","COVID",[1979],{"trials":1996,"activeCount":100},[],{"trials":1998,"activeCount":100},[],{"trials":2000,"activeCount":100},[],{"trials":2002,"activeCount":100},[],{"intervention":2004,"totalTrials":96,"cells":2005},"F18CETO",{"EARLY_PHASE1":2006,"PHASE1":2023,"PHASE2":2025,"PHASE3":2027,"PHASE4":2029,"NA":2031},{"trials":2007,"activeCount":100},[2008],{"nctId":2009,"briefTitle":2010,"status":586,"phases":2011,"primaryCompletion":2012,"completion":2013,"start":2014,"enrollment":2015,"conditions":2016,"interventions":2022},"NCT05361083","First-in-human Evaluation of [18F]CETO",[88],"2021-04-01","2022-02-28","2019-09-01",20,[2017,2018,2019,2020,2021],"Primary Aldosteronism Due to Aldosterone Producing Adenoma","Primary Aldosteronism Due to Nodular Hyperplasia","Adrenal Cushing Syndrome","Non-Secretory Adrenal Adenoma","Adrenocortical Carcinoma",[2004],{"trials":2024,"activeCount":100},[],{"trials":2026,"activeCount":100},[],{"trials":2028,"activeCount":100},[],{"trials":2030,"activeCount":100},[],{"trials":2032,"activeCount":100},[],{"intervention":2034,"totalTrials":654,"cells":2035},"oxytocin",{"EARLY_PHASE1":2036,"PHASE1":2038,"PHASE2":2040,"PHASE3":2042,"PHASE4":2044,"NA":2058},{"trials":2037,"activeCount":100},[],{"trials":2039,"activeCount":100},[],{"trials":2041,"activeCount":100},[],{"trials":2043,"activeCount":100},[],{"trials":2045,"activeCount":100},[2046],{"nctId":2047,"briefTitle":2048,"status":586,"phases":2049,"primaryCompletion":2050,"completion":2050,"start":2051,"enrollment":2052,"conditions":2053,"interventions":2057},"NCT00777166","Cardiac Effects of Oxytocin Administrated During Cesarean Section, Signs of Myocardial Ischemia",[92],"2008-07","2005-12",103,[2054,2055,2056],"Myocardial Ischemia","Hypotension","Bloodloss",[2034,2034],{"trials":2059,"activeCount":100},[2060],{"nctId":2061,"briefTitle":2062,"status":586,"phases":2063,"primaryCompletion":2064,"completion":2064,"start":2065,"enrollment":2066,"conditions":2067,"interventions":2069},"NCT01530230","ST- Depression on Electrocardiogram During Caesarean Section in Regional Anaesthesia in Women With Preeclampsia",[93],"2008-04","2005-11",25,[2068],"Preeclampsia",[2034],{"intervention":2071,"totalTrials":654,"cells":2072},"Caffeine",{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2077,"PHASE3":2088,"PHASE4":2090,"NA":2092},{"trials":2074,"activeCount":100},[],{"trials":2076,"activeCount":100},[],{"trials":2078,"activeCount":100},[2079],{"nctId":2080,"briefTitle":2081,"status":1010,"phases":2082,"primaryCompletion":2083,"start":666,"enrollment":2084,"conditions":2085,"interventions":2087},"NCT02311088","Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor",[90],"2015-12",26,[2086],"Dyspnea",[2071],{"trials":2089,"activeCount":100},[],{"trials":2091,"activeCount":100},[],{"trials":2093,"activeCount":100},[2094],{"nctId":2095,"briefTitle":2096,"status":586,"phases":2097,"primaryCompletion":2098,"completion":2099,"start":2100,"enrollment":2101,"conditions":2102,"interventions":2104},"NCT01815203","Caffein Consumption and Response Inhibition",[93],"2013-07","2013-08","2013-03",21,[2103,16],"Eating Behavior",[2071],{"intervention":2106,"totalTrials":96,"cells":2107},"Amiodarone",{"EARLY_PHASE1":2108,"PHASE1":2110,"PHASE2":2112,"PHASE3":2114,"PHASE4":2116,"NA":2118},{"trials":2109,"activeCount":100},[],{"trials":2111,"activeCount":100},[],{"trials":2113,"activeCount":100},[],{"trials":2115,"activeCount":100},[],{"trials":2117,"activeCount":100},[],{"trials":2119,"activeCount":100},[2120],{"nctId":2121,"briefTitle":2122,"status":733,"phases":2123,"primaryCompletion":1436,"completion":1436,"start":786,"enrollment":2124,"conditions":2125,"interventions":2127},"NCT02294955","Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial)",[93],152,[2126,32],"Atrial Fibrillation",[2106,2128,2129,2130,2131,2132],"Sotalol","Flecainide","Propafenone","Disopyramide","Dronedarone",{"intervention":2128,"totalTrials":96,"cells":2134},{"EARLY_PHASE1":2135,"PHASE1":2137,"PHASE2":2139,"PHASE3":2141,"PHASE4":2143,"NA":2145},{"trials":2136,"activeCount":100},[],{"trials":2138,"activeCount":100},[],{"trials":2140,"activeCount":100},[],{"trials":2142,"activeCount":100},[],{"trials":2144,"activeCount":100},[],{"trials":2146,"activeCount":100},[2147],{"nctId":2121,"briefTitle":2122,"status":733,"phases":2148,"primaryCompletion":1436,"completion":1436,"start":786,"enrollment":2124,"conditions":2149,"interventions":2150},[93],[2126,32],[2106,2128,2129,2130,2131,2132],{"intervention":2129,"totalTrials":96,"cells":2152},{"EARLY_PHASE1":2153,"PHASE1":2155,"PHASE2":2157,"PHASE3":2159,"PHASE4":2161,"NA":2163},{"trials":2154,"activeCount":100},[],{"trials":2156,"activeCount":100},[],{"trials":2158,"activeCount":100},[],{"trials":2160,"activeCount":100},[],{"trials":2162,"activeCount":100},[],{"trials":2164,"activeCount":100},[2165],{"nctId":2121,"briefTitle":2122,"status":733,"phases":2166,"primaryCompletion":1436,"completion":1436,"start":786,"enrollment":2124,"conditions":2167,"interventions":2168},[93],[2126,32],[2106,2128,2129,2130,2131,2132],{"intervention":2130,"totalTrials":96,"cells":2170},{"EARLY_PHASE1":2171,"PHASE1":2173,"PHASE2":2175,"PHASE3":2177,"PHASE4":2179,"NA":2181},{"trials":2172,"activeCount":100},[],{"trials":2174,"activeCount":100},[],{"trials":2176,"activeCount":100},[],{"trials":2178,"activeCount":100},[],{"trials":2180,"activeCount":100},[],{"trials":2182,"activeCount":100},[2183],{"nctId":2121,"briefTitle":2122,"status":733,"phases":2184,"primaryCompletion":1436,"completion":1436,"start":786,"enrollment":2124,"conditions":2185,"interventions":2186},[93],[2126,32],[2106,2128,2129,2130,2131,2132],{"intervention":2131,"totalTrials":96,"cells":2188},{"EARLY_PHASE1":2189,"PHASE1":2191,"PHASE2":2193,"PHASE3":2195,"PHASE4":2197,"NA":2199},{"trials":2190,"activeCount":100},[],{"trials":2192,"activeCount":100},[],{"trials":2194,"activeCount":100},[],{"trials":2196,"activeCount":100},[],{"trials":2198,"activeCount":100},[],{"trials":2200,"activeCount":100},[2201],{"nctId":2121,"briefTitle":2122,"status":733,"phases":2202,"primaryCompletion":1436,"completion":1436,"start":786,"enrollment":2124,"conditions":2203,"interventions":2204},[93],[2126,32],[2106,2128,2129,2130,2131,2132],{"intervention":2132,"totalTrials":96,"cells":2206},{"EARLY_PHASE1":2207,"PHASE1":2209,"PHASE2":2211,"PHASE3":2213,"PHASE4":2215,"NA":2217},{"trials":2208,"activeCount":100},[],{"trials":2210,"activeCount":100},[],{"trials":2212,"activeCount":100},[],{"trials":2214,"activeCount":100},[],{"trials":2216,"activeCount":100},[],{"trials":2218,"activeCount":100},[2219],{"nctId":2121,"briefTitle":2122,"status":733,"phases":2220,"primaryCompletion":1436,"completion":1436,"start":786,"enrollment":2124,"conditions":2221,"interventions":2222},[93],[2126,32],[2106,2128,2129,2130,2131,2132],{"intervention":2224,"totalTrials":96,"cells":2225},"Methylene blue",{"EARLY_PHASE1":2226,"PHASE1":2228,"PHASE2":2230,"PHASE3":2232,"PHASE4":2234,"NA":2236},{"trials":2227,"activeCount":100},[],{"trials":2229,"activeCount":100},[],{"trials":2231,"activeCount":100},[],{"trials":2233,"activeCount":100},[],{"trials":2235,"activeCount":100},[],{"trials":2237,"activeCount":100},[2238],{"nctId":2239,"briefTitle":2240,"status":586,"phases":2241,"primaryCompletion":2242,"completion":2243,"start":1561,"enrollment":20,"conditions":2244,"interventions":2246},"NCT02303886","Methylene Blue Intravenously and Chronic Neuropathic Pain",[93],"2012-06","2014-11",[2245],"Neuropathic Pain",[2224,2224],{"intervention":2248,"totalTrials":96,"cells":2249},"Ringer's Acetate",{"EARLY_PHASE1":2250,"PHASE1":2252,"PHASE2":2254,"PHASE3":2256,"PHASE4":2258,"NA":2260},{"trials":2251,"activeCount":100},[],{"trials":2253,"activeCount":100},[],{"trials":2255,"activeCount":100},[],{"trials":2257,"activeCount":100},[],{"trials":2259,"activeCount":100},[],{"trials":2261,"activeCount":100},[2262],{"nctId":2263,"briefTitle":2264,"status":1010,"phases":2265,"primaryCompletion":2266,"completion":2267,"start":2268,"enrollment":2269,"conditions":2270,"interventions":2276},"NCT03553394","Effects of Restrictive Fluid Strategy on Postoperative Oliguric Pancreatic Surgery Patients",[93],"2021-05-31","2022-08-30","2018-10-01",53,[2271,2272,2273,2274,2275],"Fluid Therapy","Postoperative Period","Postoperative Complications","Pancreas Disease","Fluid Overload",[2248],{"intervention":2278,"totalTrials":96,"cells":2279},"Antibiotic",{"EARLY_PHASE1":2280,"PHASE1":2282,"PHASE2":2284,"PHASE3":2286,"PHASE4":2288,"NA":2290},{"trials":2281,"activeCount":100},[],{"trials":2283,"activeCount":100},[],{"trials":2285,"activeCount":100},[],{"trials":2287,"activeCount":100},[],{"trials":2289,"activeCount":100},[],{"trials":2291,"activeCount":100},[2292],{"nctId":2293,"briefTitle":2294,"status":586,"phases":2295,"primaryCompletion":1612,"completion":1326,"start":2296,"enrollment":2297,"conditions":2298,"interventions":2300},"NCT01008488","Antibiotic Therapy of Acute Uncomplicated Colonic Diverticulitis",[93],"2002-11",600,[2299],"Colonic Diverticulitis",[2278],{"intervention":2302,"totalTrials":96,"cells":2303},"Icodextrin",{"EARLY_PHASE1":2304,"PHASE1":2306,"PHASE2":2308,"PHASE3":2310,"PHASE4":2312,"NA":2314},{"trials":2305,"activeCount":100},[],{"trials":2307,"activeCount":100},[],{"trials":2309,"activeCount":100},[],{"trials":2311,"activeCount":100},[],{"trials":2313,"activeCount":100},[],{"trials":2315,"activeCount":100},[2316],{"nctId":2317,"briefTitle":2318,"status":733,"phases":2319,"primaryCompletion":2320,"completion":2320,"start":2321,"enrollment":2322,"conditions":2323,"interventions":2325},"NCT02318888","Does Icodextrin Reduce the Risk of Small Bowel Obstruction?",[93],"2022-12","2009-12",1808,[2324],"Surgical Adhesions",[2302],{"intervention":2327,"totalTrials":96,"cells":2328},"Mesenchymal stem cells",{"EARLY_PHASE1":2329,"PHASE1":2331,"PHASE2":2333,"PHASE3":2335,"PHASE4":2337,"NA":2339},{"trials":2330,"activeCount":100},[],{"trials":2332,"activeCount":100},[],{"trials":2334,"activeCount":100},[],{"trials":2336,"activeCount":100},[],{"trials":2338,"activeCount":100},[],{"trials":2340,"activeCount":100},[2341],{"nctId":2342,"briefTitle":2343,"status":586,"phases":2344,"primaryCompletion":2345,"completion":2345,"start":2346,"enrollment":2015,"conditions":2347,"interventions":2349},"NCT01068951","Treatment of Patients With Newly Onset of Type 1 Diabetes With Mesenchymal Stem Cells",[93],"2013-09","2010-06",[2348],"Type 1 Diabetes",[2327],{"intervention":2351,"totalTrials":96,"cells":2352},"Sucrosomial Iron",{"EARLY_PHASE1":2353,"PHASE1":2355,"PHASE2":2357,"PHASE3":2359,"PHASE4":2361,"NA":2363},{"trials":2354,"activeCount":100},[],{"trials":2356,"activeCount":100},[],{"trials":2358,"activeCount":100},[],{"trials":2360,"activeCount":100},[],{"trials":2362,"activeCount":100},[],{"trials":2364,"activeCount":100},[2365],{"nctId":2366,"briefTitle":2367,"status":586,"phases":2368,"primaryCompletion":2369,"completion":2369,"start":2370,"enrollment":2371,"conditions":2372,"interventions":2374},"NCT05678647","Sucrosomial Iron and Iron Sulphate to Blood Donors",[93],"2026-03-01","2023-01-31",120,[2373],"Blood Donation",[2351,2375],"Iron Sulfate",{"intervention":2375,"totalTrials":96,"cells":2377},{"EARLY_PHASE1":2378,"PHASE1":2380,"PHASE2":2382,"PHASE3":2384,"PHASE4":2386,"NA":2388},{"trials":2379,"activeCount":100},[],{"trials":2381,"activeCount":100},[],{"trials":2383,"activeCount":100},[],{"trials":2385,"activeCount":100},[],{"trials":2387,"activeCount":100},[],{"trials":2389,"activeCount":100},[2390],{"nctId":2366,"briefTitle":2367,"status":586,"phases":2391,"primaryCompletion":2369,"completion":2369,"start":2370,"enrollment":2371,"conditions":2392,"interventions":2393},[93],[2373],[2351,2375],{"intervention":2395,"totalTrials":96,"cells":2396},"1 combination tablet of Vitamin D3\u002Fcalcium per day",{"EARLY_PHASE1":2397,"PHASE1":2399,"PHASE2":2401,"PHASE3":2403,"PHASE4":2405,"NA":2407},{"trials":2398,"activeCount":100},[],{"trials":2400,"activeCount":100},[],{"trials":2402,"activeCount":100},[],{"trials":2404,"activeCount":100},[],{"trials":2406,"activeCount":100},[],{"trials":2408,"activeCount":100},[2409],{"nctId":2410,"briefTitle":2411,"status":586,"phases":2412,"primaryCompletion":2413,"completion":2413,"start":1612,"enrollment":2414,"conditions":2415,"interventions":2418},"NCT02922803","Vitamin D and Physical Performance Before and After Intervention and Birth Outcome in Pregnant Somali and Swedish Women",[93],"2016-08",123,[2416,2417],"Muscle Weakness","Vitamin D Deficiency",[2395,2419],"2 combination tablets of Vitamin D3\u002Fcalcium per day",{"intervention":2419,"totalTrials":96,"cells":2421},{"EARLY_PHASE1":2422,"PHASE1":2424,"PHASE2":2426,"PHASE3":2428,"PHASE4":2430,"NA":2432},{"trials":2423,"activeCount":100},[],{"trials":2425,"activeCount":100},[],{"trials":2427,"activeCount":100},[],{"trials":2429,"activeCount":100},[],{"trials":2431,"activeCount":100},[],{"trials":2433,"activeCount":100},[2434],{"nctId":2410,"briefTitle":2411,"status":586,"phases":2435,"primaryCompletion":2413,"completion":2413,"start":1612,"enrollment":2414,"conditions":2436,"interventions":2437},[93],[2416,2417],[2395,2419],{"intervention":2439,"totalTrials":96,"cells":2440},"Feces collection",{"EARLY_PHASE1":2441,"PHASE1":2443,"PHASE2":2445,"PHASE3":2447,"PHASE4":2449,"NA":2451},{"trials":2442,"activeCount":100},[],{"trials":2444,"activeCount":100},[],{"trials":2446,"activeCount":100},[],{"trials":2448,"activeCount":100},[],{"trials":2450,"activeCount":100},[],{"trials":2452,"activeCount":100},[2453],{"nctId":2454,"briefTitle":2455,"status":733,"phases":2456,"primaryCompletion":2083,"completion":2083,"start":608,"enrollment":2015,"conditions":2457,"interventions":2463},"NCT02005003","Cognitive and Metabolic Effects of a Probiotic Supplement",[93],[2458,2459,2460,2461,2462],"Dietary Supplements","Probiotics","Metabolism","Food Preferences","Microbiota",[2439],{"intervention":2465,"totalTrials":96,"cells":2466},"Switch from calcineurin inhibitor to an mTOR inhibitor",{"EARLY_PHASE1":2467,"PHASE1":2469,"PHASE2":2471,"PHASE3":2473,"PHASE4":2475,"NA":2477},{"trials":2468,"activeCount":100},[],{"trials":2470,"activeCount":100},[],{"trials":2472,"activeCount":100},[],{"trials":2474,"activeCount":100},[],{"trials":2476,"activeCount":100},[],{"trials":2478,"activeCount":100},[2479],{"nctId":2480,"briefTitle":2481,"status":586,"phases":2482,"primaryCompletion":2483,"completion":2483,"start":2484,"enrollment":2485,"conditions":2486,"interventions":2488},"NCT02241564","Malignancies in Transplanted Patients",[],"2017-06","2007-11",95,[2487],"Neoplasms",[2465],{"intervention":2490,"totalTrials":96,"cells":2491},"TKTX-Cream",{"EARLY_PHASE1":2492,"PHASE1":2494,"PHASE2":2496,"PHASE3":2498,"PHASE4":2500,"NA":2502},{"trials":2493,"activeCount":100},[],{"trials":2495,"activeCount":100},[],{"trials":2497,"activeCount":100},[],{"trials":2499,"activeCount":100},[],{"trials":2501,"activeCount":100},[],{"trials":2503,"activeCount":100},[2504],{"nctId":2505,"briefTitle":2506,"status":733,"phases":2507,"primaryCompletion":2508,"completion":2508,"start":2509,"enrollment":2510,"conditions":2511,"interventions":2512},"NCT06326125","Pharmacology and Non-pharmacology Approaches in Reducing Children's Pain and Fear During Painful Procedures",[93],"2024-04-10","2023-12-15",160,[35],[2490],{"intervention":2514,"totalTrials":96,"cells":2515},"Molecular genetic analysis",{"EARLY_PHASE1":2516,"PHASE1":2518,"PHASE2":2520,"PHASE3":2522,"PHASE4":2524,"NA":2526},{"trials":2517,"activeCount":100},[],{"trials":2519,"activeCount":100},[],{"trials":2521,"activeCount":100},[],{"trials":2523,"activeCount":100},[],{"trials":2525,"activeCount":100},[],{"trials":2527,"activeCount":100},[2528],{"nctId":2529,"briefTitle":2530,"status":733,"phases":2531,"primaryCompletion":2532,"completion":2533,"start":2534,"enrollment":715,"conditions":2535,"interventions":2536},"NCT03130205","Biomarker Study in Pancreatic Neuroendocrine Tumours",[],"2021-01-01","2022-01-01","2017-05-01",[289],[2514],{"intervention":2538,"totalTrials":96,"cells":2539},"Lidocaine",{"EARLY_PHASE1":2540,"PHASE1":2542,"PHASE2":2544,"PHASE3":2546,"PHASE4":2548,"NA":2550},{"trials":2541,"activeCount":100},[],{"trials":2543,"activeCount":100},[],{"trials":2545,"activeCount":100},[],{"trials":2547,"activeCount":100},[],{"trials":2549,"activeCount":100},[],{"trials":2551,"activeCount":100},[2552],{"nctId":2553,"briefTitle":2554,"status":586,"phases":2555,"primaryCompletion":2099,"completion":2556,"start":2557,"enrollment":2558,"conditions":2559,"interventions":2560},"NCT02300038","Lidocaine and Neuroma Pain Related Modalities",[93],"2014-09","2010-04",16,[2245],[2538],{"intervention":2562,"totalTrials":96,"cells":2563},"TKTX cream",{"EARLY_PHASE1":2564,"PHASE1":2566,"PHASE2":2568,"PHASE3":2570,"PHASE4":2572,"NA":2574},{"trials":2565,"activeCount":100},[],{"trials":2567,"activeCount":100},[],{"trials":2569,"activeCount":100},[],{"trials":2571,"activeCount":100},[],{"trials":2573,"activeCount":100},[],{"trials":2575,"activeCount":100},[2576],{"nctId":2577,"briefTitle":2578,"status":586,"phases":2579,"primaryCompletion":2580,"completion":2581,"start":2582,"enrollment":2583,"conditions":2584,"interventions":2587},"NCT05957718","Effectiveness of TKTX Cream on Pain and Fear in Children During Venipuncture: A Randomized Controlled Trial",[93],"2023-02-03","2023-09-04","2022-08-02",88,[35,2585,2586],"Fear of Pain","Venipuncture Site Numbness",[2562],{"intervention":2589,"totalTrials":96,"cells":2590},"Iodine-containing Contrast Media",{"EARLY_PHASE1":2591,"PHASE1":2593,"PHASE2":2595,"PHASE3":2597,"PHASE4":2599,"NA":2601},{"trials":2592,"activeCount":100},[],{"trials":2594,"activeCount":100},[],{"trials":2596,"activeCount":100},[],{"trials":2598,"activeCount":100},[],{"trials":2600,"activeCount":100},[],{"trials":2602,"activeCount":100},[2603],{"nctId":2604,"briefTitle":2605,"status":733,"phases":2606,"primaryCompletion":2607,"completion":2608,"start":2609,"enrollment":2610,"conditions":2611,"interventions":2613},"NCT06171958","Incidence of Acute Kidney Injury After Administration of Iodine Contrast Media in Patients With Reduced Renal Function",[],"2025-07-31","2025-12-31","2024-01-24",400,[2612],"Acute Kidney Injury Following Administration of Contrast Media",[2589],{"intervention":2615,"totalTrials":96,"cells":2616},"Anesthesia Agent",{"EARLY_PHASE1":2617,"PHASE1":2619,"PHASE2":2621,"PHASE3":2623,"PHASE4":2625,"NA":2627},{"trials":2618,"activeCount":100},[],{"trials":2620,"activeCount":100},[],{"trials":2622,"activeCount":100},[],{"trials":2624,"activeCount":100},[],{"trials":2626,"activeCount":100},[],{"trials":2628,"activeCount":100},[2629],{"nctId":2630,"briefTitle":2631,"status":733,"phases":2632,"primaryCompletion":2633,"completion":2608,"start":2634,"enrollment":2635,"conditions":2636,"interventions":2638},"NCT05585866","Propofol and Sevoflurane Anesthesia in Colorectal Cancer Surgery: Incidence of Acute Kidney Injury",[],"2022-10-31","2021-11-22",4000,[30,2637],"Cancer Colorectal",[2615],{"intervention":2640,"totalTrials":96,"cells":2641},"Beta Blocker Therapy or No Therapy",{"EARLY_PHASE1":2642,"PHASE1":2644,"PHASE2":2646,"PHASE3":2648,"PHASE4":2650,"NA":2652},{"trials":2643,"activeCount":100},[],{"trials":2645,"activeCount":100},[],{"trials":2647,"activeCount":100},[],{"trials":2649,"activeCount":100},[],{"trials":2651,"activeCount":100},[],{"trials":2653,"activeCount":100},[2654],{"nctId":2655,"briefTitle":2656,"status":586,"phases":2657,"primaryCompletion":2658,"completion":2658,"start":2659,"enrollment":2660,"conditions":2661,"interventions":2663},"NCT06736353","Effect of Classic Secondary Prevention in Type 2 MI: A Target Trial Emulation Study",[],"2022-05-05","2010-09-03",14000,[2662],"Myocardial Infarction Type 2",[2640,2664,2665,2666,2667],"RAAS blocker Therapy or No therapy","Statin Therapy or No Therapy","Single Antiplatelet Therapy or No Therapy","Dual Antiplatelet Therapy or No Therapy",{"intervention":2664,"totalTrials":96,"cells":2669},{"EARLY_PHASE1":2670,"PHASE1":2672,"PHASE2":2674,"PHASE3":2676,"PHASE4":2678,"NA":2680},{"trials":2671,"activeCount":100},[],{"trials":2673,"activeCount":100},[],{"trials":2675,"activeCount":100},[],{"trials":2677,"activeCount":100},[],{"trials":2679,"activeCount":100},[],{"trials":2681,"activeCount":100},[2682],{"nctId":2655,"briefTitle":2656,"status":586,"phases":2683,"primaryCompletion":2658,"completion":2658,"start":2659,"enrollment":2660,"conditions":2684,"interventions":2685},[],[2662],[2640,2664,2665,2666,2667],{"intervention":2665,"totalTrials":96,"cells":2687},{"EARLY_PHASE1":2688,"PHASE1":2690,"PHASE2":2692,"PHASE3":2694,"PHASE4":2696,"NA":2698},{"trials":2689,"activeCount":100},[],{"trials":2691,"activeCount":100},[],{"trials":2693,"activeCount":100},[],{"trials":2695,"activeCount":100},[],{"trials":2697,"activeCount":100},[],{"trials":2699,"activeCount":100},[2700],{"nctId":2655,"briefTitle":2656,"status":586,"phases":2701,"primaryCompletion":2658,"completion":2658,"start":2659,"enrollment":2660,"conditions":2702,"interventions":2703},[],[2662],[2640,2664,2665,2666,2667],{"intervention":2666,"totalTrials":96,"cells":2705},{"EARLY_PHASE1":2706,"PHASE1":2708,"PHASE2":2710,"PHASE3":2712,"PHASE4":2714,"NA":2716},{"trials":2707,"activeCount":100},[],{"trials":2709,"activeCount":100},[],{"trials":2711,"activeCount":100},[],{"trials":2713,"activeCount":100},[],{"trials":2715,"activeCount":100},[],{"trials":2717,"activeCount":100},[2718],{"nctId":2655,"briefTitle":2656,"status":586,"phases":2719,"primaryCompletion":2658,"completion":2658,"start":2659,"enrollment":2660,"conditions":2720,"interventions":2721},[],[2662],[2640,2664,2665,2666,2667],{"intervention":2667,"totalTrials":96,"cells":2723},{"EARLY_PHASE1":2724,"PHASE1":2726,"PHASE2":2728,"PHASE3":2730,"PHASE4":2732,"NA":2734},{"trials":2725,"activeCount":100},[],{"trials":2727,"activeCount":100},[],{"trials":2729,"activeCount":100},[],{"trials":2731,"activeCount":100},[],{"trials":2733,"activeCount":100},[],{"trials":2735,"activeCount":100},[2736],{"nctId":2655,"briefTitle":2656,"status":586,"phases":2737,"primaryCompletion":2658,"completion":2658,"start":2659,"enrollment":2660,"conditions":2738,"interventions":2739},[],[2662],[2640,2664,2665,2666,2667],{"intervention":2741,"totalTrials":96,"cells":2742},"bDMARD treatment",{"EARLY_PHASE1":2743,"PHASE1":2745,"PHASE2":2747,"PHASE3":2749,"PHASE4":2751,"NA":2753},{"trials":2744,"activeCount":100},[],{"trials":2746,"activeCount":100},[],{"trials":2748,"activeCount":100},[],{"trials":2750,"activeCount":100},[],{"trials":2752,"activeCount":100},[],{"trials":2754,"activeCount":100},[2755],{"nctId":2756,"briefTitle":2757,"status":586,"phases":2758,"primaryCompletion":2083,"completion":2759,"start":1662,"enrollment":2760,"conditions":2761,"interventions":2764},"NCT02840695","Effect of Biological Disease Modifying Anti Rheumatic Drug (bDMARD) Treatment on Spinal Fracture Incidence in Patients With Ankylosing Spondylitis (AS)",[],"2017-10-24",9858,[2762,2763],"Ankylosing Spondylitis","Spinal Fractures",[2741]]